You are here » Home » Companies » Laurus Labs Ltd - Announcements

Laurus Labs Ltd.

BSE: 540222 Sector: Health care
NSE: LAURUSLABS ISIN Code: INE947Q01010
BSE 00:00 | 15 Nov 341.80 -12.90
(-3.64%)
OPEN

354.30

HIGH

355.80

LOW

337.30

NSE 00:00 | 15 Nov 342.10 -13.35
(-3.76%)
OPEN

357.95

HIGH

357.95

LOW

337.50

Announcement under Regulation 30 (LODR)-Press Release / Media Release

September 5, 2019, 10:41 am | Source: BSE | Downlaod PDFDownload PDF

The Company is pleased to announce that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3 located at Parawada Visakhapatnam for the inspection conducted in June 2019.

And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).

A press release to this extent is attached for your information and records.